|
Accrued
expenses and other liabilities, summarized by major category, consist of the following for years ended December 31, 2022 and 2021:
Schedule of Accrued Expenses
| |
|
|
2022 |
|
|
|
2021 |
|
| |
|
As of December 31, |
|
| |
|
2022 |
|
|
2021 |
|
| Payroll and incentives |
|
$ |
1,705 |
|
|
$ |
1,343 |
|
| Deferred revenue * |
|
|
721 |
|
|
|
33 |
|
| General and administrative expenses |
|
|
455 |
|
|
|
195 |
|
| Research and development expenses |
|
|
130 |
|
|
|
381 |
|
| Other deferred liabilities ** |
|
|
88 |
|
|
|
899 |
|
| Total |
|
$ |
3,099 |
|
|
$ |
2,851 |
|
| * |
At
December 31, 2022, the balance included $688 related to an exclusive research collaboration with BioNTech SE (the “BioNTech
Agreement”) and $33 is related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”).
Both balances are expected to be recognized by March 31, 2023. At December 31, 2021, the balance of $33 was related to the Genentech
Agreement. (See Note 9 – Revenue
Recognition, Collaboration Agreements, and Other research and Development Agreements). |
| ** |
At
December 31, 2022 and December 31, 2021, the balances of $88 and $899, respectively, related to an award agreement with the Cystic
Fibrosis Foundation (the “CFF Agreement). (See Note 9 – Revenue Recognition, Collaboration Agreements, and Other Research
and Development Agreements). |
|